Abvc Biopharma, Inc. ABVC
Abvc Biopharma, Inc. (Nasdaq: ABVC) is a CNS/neurology/psychiatry drug developer. Its lead program, ABV-1505, is in Phase 2 for Adult attention-deficit hyperactivity disorder (ADHD). Its next catalyst on record is ABV-1702: Phase II start (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ABV-1702 — Phase II start (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ABV-1505 | Adult ADHD | small molecule | Phase 2 |
| ABV-1504 | Major depressive disorder | small molecule | Phase 2 |
| ABV-1701 (Vitargus) | Vitreous substitute in vitrectomy surgery (retinal detachment) | device-combination | Phase 2 |
| ABV-1601 | Depression in cancer patients | small molecule | Phase 1 |
| ABV-1702 | Myelodysplastic syndrome | botanical extract | Pre-clinical |
| ABV-1703 | Pancreatic cancer | botanical extract | Pre-clinical |
| ABV-1519 | EGFR+ non-small cell lung cancer | botanical extract | Pre-clinical |
| ABV-1501 | Triple negative breast cancer | botanical extract | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.